Holen Sie sich die Stockscreener-App
297.45
1.02%
-3.06
Schlusskurs vom Vortag:
$300.51
Offen:
$299.12
24-Stunden-Volumen:
681.26K
Relative Volume:
0.63
Marktkapitalisierung:
$39.71B
Einnahmen:
$4.29B
Nettoeinkommen (Verlust:
$577.22M
KGV:
70.68
EPS:
4.2086
Netto-Cashflow:
$641.34M
1W Leistung:
+3.65%
1M Leistung:
-4.23%
6M Leistung:
-31.84%
1J Leistung:
+2.92%
1-Tages-Spanne:
$294.99
$303.33
1-Wochen-Bereich:
$284.38
$303.33
52-Wochen-Spanne:
$284.19
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Mixed Share Performance And Strong AMVUTTRA Uptake - simplywall.st
Director at Alnylam (NASDAQ: ALNY) granted RSUs and stock options - Stock Titan
Alnylam (NASDAQ: ALNY) awards RSUs and options to board director - Stock Titan
Director at Alnylam (NASDAQ: ALNY) receives RSUs and options - Stock Titan
Alnylam (ALNY) director gets new RSUs, options and reports trust holdings - Stock Titan
Director Peter Kellogg granted RSUs and stock options at Alnylam (NASDAQ: ALNY) - Stock Titan
ALNY (ALNY) director granted 671 RSUs and 1,441 options at $298.48 - Stock Titan
Alnylam (ALNY) director Olivier Brandicourt receives new RSU and option grants - Stock Titan
ALNY (ALNY) director Dennis Ausiello granted RSUs and stock options awards - Stock Titan
Alnylam (ALNY) director granted RSUs and stock options in new equity awards - Stock Titan
Discipline and Rules-Based Execution in ALNY Response - Stock Traders Daily
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
Alnylam Pharmaceuticals’ SWOT analysis: stock faces margin pressure By Investing.com - Investing.com South Africa
Alnylam Pharmaceuticals’ SWOT analysis: stock faces margin pressure - Investing.com
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth - Eastern Progress
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
ALNY Technical Analysis & Stock Price Forecast - Intellectia AI
ALNY Initiated Coverage by Citigroup -- Price Target Set at $380 - GuruFocus
Citi Initiates Coverage on Biotech Stocks: Ionis (IONS), Alnylam (ALNY), BioMarin (BMRN) - GuruFocus
Ionis, Alnylam, BioMarin are new Buys at Citi (ALNY:NASDAQ) - Seeking Alpha
Alnylam Issues 2025 Corporate Responsibility Report - BioSpace
How HELIOS-B Phase 3 Vutrisiran Data and Real-World Evidence Expansion Will Impact Alnylam (ALNY) Investors - simplywall.st
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout - Proactive financial news
Citigroup initiates coverage of Alnylam Pharmaceuticals (ALNY) with buy recommendation - MSN
Daily Brief Health Care: Dermavon Holdings, Alebund Pharmaceuticals Jiangsu, Alnylam Pharmaceuticals, Artrya , Bavarian Nordic A/S, Cardinal Health, Dexcom Inc, American Shared Hospital Servi, Eli Lilly & Co, Abeona Therapeutics and more - Smartkarma
Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment - GlobeNewswire Inc.
How Investors Are Reacting To Alnylam Pharmaceuticals (ALNY) New HELIOS-B Vutrisiran Data And Real-World Study - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by iA Global Asset Management Inc. - MarketBeat
Alnylam’s Vutrisiran Data And Real-World Study Contrast With Depressed Valuation - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Position Reduced by DNB Asset Management AS - MarketBeat
Is the options market predicting a spike in Alnylam Pharmaceuticals stock? - MSN
ALNY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by ANTIPODES PARTNERS Ltd - MarketBeat
Alnylam Pharmaceuticals Adjusts Valuation Grade Amid Strong Financial Performance Indicators - Markets Mojo
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As HELIOS B Data And TTR Guidance Reassure Investors - simplywall.st
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Alnylam teams up with Viz.ai and American Heart Association to advance ATTR-CM care - MSN
Alnylam reiterates 2026 TTR sales guidance of $4.4B-$4.7B while expanding TRITON-CM enrollment to about 1,750 - MSN
Alnylam (NASDAQ: ALNY) director exercises 11,250 stock options at $70.20 - Stock Titan
Is Alnylam (ALNY) One of the Best Aggressive Growth Stocks to Buy? - Insider Monkey
Capital World Investors holds 10.9M Alnylam shares (NASDAQ: ALNY) - Stock Titan
Capital Research holds 9.47M shares of Alnylam (NASDAQ: ALNY) in 13G/A - Stock Titan
Alnylam Pharmaceuticals stock (US02005N1000): Backs TTR revenue outlook amid AMVUTTRA growth - AD HOC NEWS
5 Best Aggressive Growth Stocks to Buy According to Wall Street Analysts - Insider Monkey
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build - sharewise.com
ALNY: Strong AMVUTTRA growth, ambitious pipeline, and robust cash position drive future expansion - TradingView
Morgan Stanley Increases Price Goal on Alnylam Pharmaceuticals, Inc. (ALNY) - Insider Monkey
Alnylam Pharmaceuticals stock (US02005N1000): Q1 earnings beat and vutrisiran data - AD HOC NEWS
Alnylam (ALNY) Reports Positive Phase 3 Results for Vutrisiran i - GuruFocus
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden - BioSpace
Heart drug vutrisiran tied to fewer deaths in ATTR-CM patients - Stock Titan
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McLaughlin Melissa | Chief Human Resources Officer |
Apr 06 '26 |
Sale |
330.42 |
2,286 |
755,329 |
9,443 |
| McLaughlin Melissa | Chief Human Resources Officer |
Apr 02 '26 |
Sale |
319.59 |
1,624 |
519,014 |
11,729 |
1.41%
0.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):